Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 9/20 | 0.58 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938730 | 1.00 | KMO (0.58) | KMOGRM5MAPK8MAPK10KDM4E | |
| SCHEMBL1938323 | 0.81 | KMO (0.61) | KMOABL1 | |
| SCHEMBL30429823 | 0.81 | KMO (0.61) | KMOABL1 | |
| Hydrochloric Acid SCHEMBL1939287 | 0.80 | KMO (0.60) | KMOABL1 | |
| SCHEMBL30428933 | 0.77 | KMO (0.64) | KMOROCK2LIMK1 | |
| SCHEMBL1939221 | 0.77 | KMO (0.64) | KMOROCK2LIMK1 | |
| SCHEMBL16217820 | 0.76 | KMO (0.59) | KMOABL1 | |
| SCHEMBL1938804 | 0.76 | KMO (0.59) | KMOABL1 | |
| SCHEMBL30429853 | 0.76 | KMO (0.59) | KMOABL1 | |
| SCHEMBL30428914 | 0.76 | KMO (0.59) | KMOABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-116323583-A | Heterobiaryl compounds and imaging agents for imaging huntingtin | CHDI基金会股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192819-A1 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2L | KMO 4249/4885GRM5 1030/4885MAPK8 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.